Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.11 USD | -5.18% | +0.65% | +53.96% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 186.5 | 179.9 | 156.2 | 48.85 | 134.9 | 283.1 | - | - |
Enterprise Value (EV) 1 | 197.5 | 185 | 179.8 | 73.73 | 138.5 | 280.5 | 298.6 | 292.1 |
P/E ratio | -2.23 x | -3.22 x | -2.1 x | -0.81 x | -15.5 x | -5.74 x | -7.49 x | -19 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 3.54 x | 3.92 x | 3.07 x | 1.02 x | 2.67 x | 5.66 x | 4.82 x | 3.62 x |
EV / Revenue | 3.75 x | 4.03 x | 3.54 x | 1.55 x | 2.74 x | 5.61 x | 5.08 x | 3.73 x |
EV / EBITDA | -3.97 x | -4.69 x | -5.67 x | -2.09 x | -12 x | -11 x | -11.5 x | -27.6 x |
EV / FCF | -3.21 x | -4.02 x | -5.3 x | -6.82 x | - | -13.9 x | -9.74 x | -14.3 x |
FCF Yield | -31.2% | -24.9% | -18.9% | -14.7% | - | -7.2% | -10.3% | -7% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 32,043 | 33,620 | 40,164 | 54,156 | 66,767 | 91,039 | - | - |
Reference price 2 | 5.820 | 5.350 | 3.890 | 0.9021 | 2.020 | 3.110 | 3.110 | 3.110 |
Announcement Date | 3/11/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 52.61 | 45.85 | 50.83 | 47.68 | 50.58 | 50.02 | 58.76 | 78.21 |
EBITDA 1 | -49.76 | -39.45 | -31.72 | -35.3 | -11.56 | -25.47 | -26.07 | -10.6 |
EBIT 1 | -52.67 | -42.89 | -34.68 | -42.07 | -15.1 | -29.63 | -26.2 | -6.922 |
Operating Margin | -100.11% | -93.55% | -68.22% | -88.23% | -29.86% | -59.23% | -44.59% | -8.85% |
Earnings before Tax (EBT) 1 | -66.25 | -55.78 | -70.54 | -54.41 | -7.625 | -45.17 | -36.77 | -7.259 |
Net income 1 | -66.25 | -55.78 | -70.54 | -54.41 | -7.87 | -45.12 | -37.78 | -16.71 |
Net margin | -125.92% | -121.67% | -138.77% | -114.11% | -15.56% | -90.22% | -64.29% | -21.36% |
EPS 2 | -2.610 | -1.660 | -1.850 | -1.120 | -0.1300 | -0.5420 | -0.4150 | -0.1633 |
Free Cash Flow 1 | -61.55 | -45.98 | -33.89 | -10.81 | - | -20.2 | -30.65 | -20.45 |
FCF margin | -117% | -100.28% | -66.67% | -22.68% | - | -40.38% | -52.16% | -26.15% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/11/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 11.08 | 12.27 | 13.26 | 11.46 | 10.68 | 11.13 | 13.24 | 13 | 13.21 | 12.05 | 12.46 | 12.61 | 12.82 | 13.27 | 14 |
EBITDA 1 | -10.94 | -9.011 | -9.874 | -7.722 | -9.604 | -3.936 | -3.272 | -1.339 | -2.757 | -7.17 | -5.833 | -5.692 | -7.492 | - | - |
EBIT 1 | -11.67 | -9.738 | -12.76 | -8.853 | -10.71 | -11.13 | -4.209 | -2.377 | -3.911 | -8.957 | -7.044 | -6.955 | -7.448 | -6.8 | -6.6 |
Operating Margin | -105.33% | -79.36% | -96.21% | -77.23% | -100.29% | -100% | -31.79% | -18.28% | -29.62% | -74.31% | -56.54% | -55.18% | -58.12% | -51.26% | -47.14% |
Earnings before Tax (EBT) 1 | -28.94 | -13.22 | -16.3 | -12.54 | -12.35 | 8.068 | -5.508 | -2.175 | -8.01 | -12.83 | -10.62 | -10.34 | -11.34 | - | - |
Net income 1 | -28.94 | -13.22 | -16.3 | -12.54 | -12.35 | 8.068 | -5.792 | -2.035 | -8.111 | -12.83 | -10.81 | -10.55 | -10.88 | - | - |
Net margin | -261.28% | -107.74% | -122.89% | -109.36% | -115.63% | 72.46% | -43.74% | -15.65% | -61.42% | -106.43% | -86.81% | -83.71% | -84.88% | - | - |
EPS 2 | -0.7300 | -0.3200 | -0.3600 | -0.2300 | -0.2300 | 0.1100 | -0.1000 | -0.0300 | -0.1200 | -0.1700 | -0.1240 | -0.1220 | -0.1260 | -0.1000 | -0.1100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/8/22 | 5/4/22 | 8/2/22 | 11/1/22 | 3/7/23 | 5/2/23 | 8/7/23 | 11/6/23 | 3/5/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 11 | 5.1 | 23.5 | 24.9 | 3.66 | - | 15.5 | 8.99 |
Net Cash position 1 | - | - | - | - | - | 2.63 | - | - |
Leverage (Debt/EBITDA) | -0.2213 x | -0.1292 x | -0.7418 x | -0.7047 x | -0.3165 x | - | -0.5933 x | -0.848 x |
Free Cash Flow 1 | -61.6 | -46 | -33.9 | -10.8 | - | -20.2 | -30.7 | -20.5 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0.66 | 0.52 | 0.91 | 1.02 | - | 0.9 | 1 | 1 |
Capex / Sales | 1.26% | 1.13% | 1.8% | 2.15% | - | 1.8% | 1.7% | 1.28% |
Announcement Date | 3/11/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.96% | 283M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- AQST Stock
- Financials Aquestive Therapeutics, Inc.